News

Gilead Starts Clinical Trial of Inhaled Remdesivir for Less-Severe COVID-19

Gilead Starts Clinical Trial of Inhaled Remdesivir for Less-Severe COVID-19

Just two weeks after receiving approval from the FDA to begin testing an inhaled formulation of their remdesivir COVID-19 treatment, Gilead kicked off a trial comprised of 60 healthy participants. The drug, given in intravenous form has shown promise, but the effects of the inhaled dosage form targeting less severe cases are still unknown. Yourway offers end-to-end protection on shipment distribution and flexible options, including direct-to-patient services, to ensure drugs in trials reach their destinations as soon as possible.

Back to Index
Media

Upcoming Event

IQPC CTS

August 24-26, 2020
Brussels, Belgium

Media

Articles

The New Normal in Clinical Trial Protection

Open chat
Come chat with us!
Hello! How can I help you?